Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - levodopa, quantity: 200 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 54.1 mg (equivalent: carbidopa, qty 50 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - levodopa, quantity: 125 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 33.8 mg (equivalent: carbidopa, qty 31.25 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - levodopa, quantity: 75 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - levodopa, quantity: 150 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 40.5 mg (equivalent: carbidopa, qty 37.5 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide; iron oxide yellow - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - levodopa, quantity: 100 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide; iron oxide yellow - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - levodopa, quantity: 50 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 13.5 mg (equivalent: carbidopa, qty 12.5 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide; iron oxide yellow - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Australia - English - Department of Health (Therapeutic Goods Administration)

stada pharmaceuticals australia pty ltd - carbidopa monohydrate, quantity: 40.5 mg (equivalent: carbidopa, qty 37.5 mg); entacapone, quantity: 200 mg; levodopa, quantity: 150 mg - tablet, film coated - excipient ingredients: trehalose dihydrate; hyprolose; magnesium stearate; microcrystalline cellulose; sodium sulfate; carmellose sodium; powdered cellulose; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Australia - English - Department of Health (Therapeutic Goods Administration)

stada pharmaceuticals australia pty ltd - entacapone, quantity: 200 mg; levodopa, quantity: 200 mg; carbidopa monohydrate, quantity: 54 mg (equivalent: carbidopa, qty 50 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; powdered cellulose; trehalose dihydrate; hyprolose; carmellose sodium; sodium sulfate; magnesium stearate; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Australia - English - Department of Health (Therapeutic Goods Administration)

stada pharmaceuticals australia pty ltd - entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 13.5 mg (equivalent: carbidopa, qty 12.5 mg); levodopa, quantity: 50 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; trehalose dihydrate; hyprolose; sodium sulfate; powdered cellulose; carmellose sodium; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Australia - English - Department of Health (Therapeutic Goods Administration)

stada pharmaceuticals australia pty ltd - entacapone, quantity: 200 mg; levodopa, quantity: 100 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg) - tablet, film coated - excipient ingredients: sodium sulfate; powdered cellulose; hyprolose; trehalose dihydrate; magnesium stearate; carmellose sodium; microcrystalline cellulose; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.